Neoleukin Therapeutics Appoints Holly K. Vance as General Counsel

SEATTLE, Oct. 20, 2020 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Holly K. Vance as General Counsel.

Ms. Vance joins Neoleukin from the Bill & Melinda Gates Foundation, where she served as Associate General Counsel and provided legal and strategic guidance on investments and transactions to the foundation’s Strategic Investment Fund with a focus in the life sciences sector. Prior to joining the Gates Foundation, Ms. Vance was a partner in the Seattle office of the global law firm K&L Gates LLP, where she practiced corporate and securities law.

“Holly brings a wealth of legal experience across a wide range of corporate and transactional matters to Neoleukin. Her leadership role at the Gates Foundation Strategic Investment Fund combined with her scientific and healthcare background will be invaluable to the company, and we are very excited to have her join our leadership team,” said Jonathan Drachman, M.D., Chief Executive Officer of Neoleukin.

“I’m pleased to join Neoleukin at this exciting time and look forward to being actively involved in the company’s strategic initiatives,” said Ms. Vance.

Ms. Vance received a J.D. from the University of Washington School of Law, a Pharm.D. from the University of Washington School of Pharmacy, and B.S. degrees in Cell and Molecular Biology and Pharmacy from the University of Washington.

About Neoleukin Therapeutics, Inc.

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.  Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: